Latest Research: Safety and immunogenicity of investigational tuberculosis vaccine M72/AS01E–4 in people living with HIV in South Africa: an observer-blinded, randomised, controlled, phase 2 trial
Associate Professor Michele Tameris has co-authored a paper titled: "Safety and immunogenicity of investigational tuberculosis vaccine M72/AS01E in people living with HIV in South Africa", appearing in the Lancet HIV journal. The two-dose regimen of the M72/AS01E–4 tuberculosis vaccine was immunogenic, with an acceptable safety profile. The study results has led to the inclusion of people living with HIV in the ongoing global registration phase 3 trial.
